Trial Profile
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of its Effects on the Inflammatory, Fibrosis,Diabetes and Obesity Biomarkers in Subjects with Alstrom Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Fezagepras (Primary)
- Indications Alstrom's Syndrome
- Focus Adverse reactions
- Sponsors ProMetic Biosciences
- 13 Nov 2018 Results determining if PBI-4050 can improve liver fibrosis in Alstrom syndrome patients, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
- 28 Aug 2018 Status changed from active, no longer recruiting to completed.
- 14 Apr 2018 Results of the interim analysis, presented at The International Liver Congress 2018